Mentions
Extended reach
Total likes
Video views
AI synopsis
Participants are excitedly anticipating the release of ORBITA-2's results, as seen in posts that express curiosity about whether the outcomes will be positive. Words like 'amazing' and phrases like 'this is going to be pivotal' reflect a tone of high enthusiasm and expectation. Furthermore, technical discussions about the sample size and study design demonstrate a blend of interest and academic discourse, suggesting the trial could have considerable ramifications for treatment strategies in angina.
The majority of discussions indicate a favorable view towards the trial's design and potential outcomes.
Participants express strong curiosity about the trial and its implications for treating stable angina.
While many posts acknowledge the trial, only some provide detailed insights or critiques.
There is a consensus that the findings of ORBITA-2 will significantly inform clinical practices and patient care.
Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here, oh my. (I bet it will, at least partially) Here is the paper -- https://t.co/I1Ta53v7ZV Check out this table> Congrats @rallamee et al https://t.co/CrgwJw9JAC
ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications. An ordinal clinical outcome scale for angina was designed in partnership with patients to be a relevant and inclusive primary outcome https://t.co/7UMBozEd1p https://t.co/v88SqFBhwI
ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications. An ordinal clinical outcome scale for angina was designed in partnership with patients to be a relevant and inclusive primary outcome. https://t.co/kjYmYtV6jT https://t.co/2lFZNWgMs8
ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications. An ordinal clinical outcome scale for angina was designed in partnership with patients to be a relevant and inclusive primary outcome https://t.co/7UMBozEd1p https://t.co/GGSE4wsIB7
Estamos todos igual? Esperando los resultados de Orbita 2. Pueden no ser positivos? Veremos mañana. https://t.co/7dZwsJnWhH https://t.co/xiscBZW4t6
#AHA23 Interested in this: LATE-BREAKING SCIENCE
Join us as Dr. John McDougall and his team share insights on maintaining a healthy menstrual cycle. They discuss recent health topics including randomized control trials, the impact of dietary choices, and managing…
RT @jpcostabel: Estamos todos igual? Esperando los resultados de Orbita 2. Pueden no ser positivos? Veremos mañana. https://t.co/7dZwsJnWhH…
RT @DrMarthaGulati: Coming up #aha23 Refresher of trial:
RT @monaltiren: #AHA23 Interested in this: LATE-BREAKING SCIENCE
RT @DrMarthaGulati: Coming up #aha23 Refresher of trial:
Coming up #aha23 Refresher of trial:
#ORBITA2 https://t.co/LXObyKAqwA
RT @monaltiren: #AHA23 Interested in this: LATE-BREAKING SCIENCE
RT @jpcostabel: Estamos todos igual? Esperando los resultados de Orbita 2. Pueden no ser positivos? Veremos mañana. https://t.co/7dZwsJnWhH…
RT @jpcostabel: Estamos todos igual? Esperando los resultados de Orbita 2. Pueden no ser positivos? Veremos mañana. https://t.co/7dZwsJnWhH…
Estamos todos igual? Esperando los resultados de Orbita 2. Pueden no ser positivos? Veremos mañana. https://t.co/7dZwsJnWhH https://t.co/xiscBZW4t6
RT @monaltiren: #AHA23 Interested in this: LATE-BREAKING SCIENCE
ORBITA2デザイン論文: https://t.co/uZTrD2Orfh
RT @monaltiren: #AHA23 Interested in this: LATE-BREAKING SCIENCE
#AHA23 Interested in this: LATE-BREAKING SCIENCE
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
RT @drjohnm: Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here,…
Reviewing some #aha23 material ORBITA-2 is going to be amazing. What a test! If PCI doesn't prove placebo resistant here, oh my. (I bet it will, at least partially) Here is the paper -- https://t.co/I1Ta53v7ZV Check out this table> Congrats @rallamee et al https://t.co/CrgwJw9JAC
@f2harrell @GreggWStone @pocock_stuart @kaulcsmc @mmamas1973 @stephensenn @vandy_biostat ORBITA 2 (DOI: 10.4244/EIJ-D-21-00649) is designed with longitudinal ordinal outcome + Bayes. The planned sample size is 400. What would be the corresponding sample size with the win ratio? When are the results expected?
A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial via @EuroInterventio https://t.co/tLeVh3ffBG
@mikejohansenmd @DavidLBrownMD @venkmurthy https://t.co/fF6HaxSBdv What do you think about ORBITA-2? Angina frequency at 12 wks is the PEP. @AlexNowbar, @rallamee
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
@ProfDFrancis et al. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial via Via @EuroInterventio https://t.co/6J1YWTQ5qZ
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications. An ordinal clinical outcome scale for angina was designed in partnership with patients to be a relevant and inclusive primary outcome https://t.co/7UMBozEd1p https://t.co/GGSE4wsIB7
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial via @EuroInterventio https://t.co/408wRharqU
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
RT @EuroInterventio: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medicatio…
ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications. An ordinal clinical outcome scale for angina was designed in partnership with patients to be a relevant and inclusive primary outcome https://t.co/7UMBozEd1p https://t.co/v88SqFBhwI
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
RT @DFCapodanno: ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications.…
ORBITA-2 will provide placebo-controlled data on the efficacy of PCI on symptoms in patients off antianginal medications. An ordinal clinical outcome scale for angina was designed in partnership with patients to be a relevant and inclusive primary outcome. https://t.co/kjYmYtV6jT https://t.co/2lFZNWgMs8